“Their collective experience is a valuable addition as we continue shaping the path ahead for Aardvark.” Timothy Kieffer, Ph.D., is a globally recognized academic leader in diabetes ...

SEQUIM, Wash. — Ty Coone's friends and family are just beginning to process the loss of the 21-year-old fisherman, who went missing earlier this week near the Dungeness Spit. They describe him ...

Aardvark Therapeutics, Inc. announced progress in its Phase 3 HERO trial for ARD-101, aimed at treating hyperphagia associated with Prader-Willi Syndrome, with data expected in early 2026. The ...

SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule ...

Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS); data readout expected in early 2026 $151.3 million in cash, cash equivalents, and short ...

A new AI weather prediction system called Aardvark Weather delivers accurate forecasts faster with thousands of times less computing power than current AI and physics-based forecasting systems.

How can artificial intelligence (AI) help predict weather forecasts with better accuracy and efficiency than current weather forecast methods? This is what a recent study published in Nature hopes to ...

Shares of obesity drug developer Aardvark Therapeutics (NASDAQ:AARD) closed 11% lower following the company's $94M initial public offering. Aardvark (NASDAQ:AARD) shares opened at $15.18 after ...

While Aardvark Therapeutics is interested in serving this market, first it wants to validate its approach by treating patients whose excessive eating is rooted in a rare genetic disorder.

Obesity-focused Aardvark Therapeutics is heading to the Nasdaq this morning in an IPO that matched the low end of its expectations. The company’s 5.9 million shares will be offered at $16 apiece ...

Aardvark Therapeutics announces IPO pricing at $16 per share, aiming to raise approximately $94.2 million for metabolic disease research. Aardvark Therapeutics, Inc., a clinical-stage ...

SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (“Aardvark”) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule ...